Twist Bioscience
TWST
198 hedge funds and large institutions have $1.43B invested in Twist Bioscience in 2022 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 79 increasing their positions, 51 reducing their positions, and 45 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 51
16% more call options, than puts
Call options by funds: $6.65M | Put options by funds: $5.74M
3.98% more ownership
Funds ownership: 103.48% → 107.46% (+4%)
10% less funds holding
Funds holding: 221 → 198 (-23)
30% less capital invested
Capital invested by funds: $2.04B → $1.43B (-$611M)
42% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 45
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$45.3M |
| 2 |
JP Morgan Chase
New York
|
+$18.2M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$17.7M |
| 4 |
BlackRock
New York
|
+$16.9M |
| 5 |
CC
Casdin Capital
New York
|
+$16.8M |
Top Sellers
| 1 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
-$28.4M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$16.6M |
| 3 |
Morgan Stanley
New York
|
-$14.5M |
| 4 |
Millennium Management
New York
|
-$12.8M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$12.1M |
TWST Hedge Fund Activity: Q4 2022 in Review
198 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Twist Bioscience (TWST) for Q4 2022, worth a combined $1.43B — down 30% from $2.04B a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of TWST and 26 opened new positions — a net loss of 19 holders — while 51 trimmed existing stakes and 79 added.
The largest buyer was State Street, adding an estimated $45.3M. The largest seller was Blue Water Life Science Advisors, exiting entirely with an estimated $28.4M sold.
- 198 institutional investors held Twist Bioscience (TWST) as of Q4 2022, down from 221 in Q3 2022.
- Funds reported $1.43B of Twist Bioscience stock for Q4 2022, down 30% quarter-over-quarter.
- 26 funds opened new Twist Bioscience positions in Q4 2022 and 45 closed out, a net change of -19 holders.
- The largest Twist Bioscience buyer in Q4 2022 was State Street, an estimated $45.3M added.
- The largest Twist Bioscience seller in Q4 2022 was Blue Water Life Science Advisors, an estimated $28.4M sold.
Based on aggregated 13F filings for Q4 2022.